氟伐他汀联合非诺贝特治疗混合性高脂血症的可行性探讨

目的观察氟伐他汀联合非诺贝特治疗混合性高脂血症的临床效果。方法选择2007年1月至2008年12月南通市老年康复医院心内科门诊混合性高脂血症患者180例,随机分为氟伐他汀组、非诺贝特组、联合用药组各60例;氟伐他汀组每晚口服40mg氟伐他汀、非诺贝特组每晚口服非诺贝特200mg、联合用药每日清晨口服非诺贝特200mg,晚口服氟伐他汀20mg,均用至12周。观察血脂参数变化、疗效评价、药物主要不良反应。结果三组TC、LDL-C、TG治疗前无差异(P>0.05),氟伐他汀组治疗后TC、LDL-C均有显著性下降(P<0.05),TG变化不明显(P>0.05);非诺贝特组治疗后TG有显著性下降(P<0.05),TC、LDL-C变化不明显(P>0.05);联合用药组TC、LDL-C、TG均有显著性下降(P<0.05)。联合用药组临床控制(显效、好转)83.3%(50/60)高于氟伐他汀组的68.3%(41/60)和非诺贝特组的65.0%。三组患者血清CK、肝肾功能等参数均无明显变化,未出现肌病症状,无1例退出或终止。结论氟伐他汀联合非诺贝特对混合性高脂血症具有良好的安全性与耐受性,具有临床应用可行性。

Study on combined therapy with fluvastatin and fenofibrate in patients with combined hyperlipidemia

Objective To investigate the effcacy and safety of combined therapy with fluvastatin andfenofibrate in patients with combined hyperlipidemia. Result Select January 2007 - December 2008 in our hospital out-patient cardiac medicine in patients with mixed hyperlipidemia were randomly divided into 180 cases of fluvastatin group, fenofibrate group, combination therapy group 60 cases; Fluvastatin group nightly 40mg oral fluvastatin, fenofibrate group night oral fenofibrate 200rag, combined dally morning oral fenofibrate 200mg, late oral fluvastatin 20mg, both use to 12 weeks. Observed changes in lipid parameters, efficacy evaluation of major adverse drug. Method Three group TC, LDL-C, TG no difference before treatment （P〉0.05）, fluvastatin group after treatment, TC, LDL-C were significantly decreased （P〈0.05）, TG did not change significantly （P〉0.05）; Fenofibrate treatment group TG were significantly decreased （P 〈0.05）, TC, LDL-C did not change significantly （P〉0.05）;combined medication group TC, LDL-C, TG were significantly decreased （P〈0.05）. Combined clinical control （markedly improved） 83.3% （50/60） than in fluvastatin group 68.3% （41/60）, fenofibrate group 65.0%. Three groups of serum CK, liver and renal function parameters such as no significant changes in symptoms of myopathy does not appear, no exit or termination of Example. Conclusions Combination therapy with fluvastatin and fenofibrate is more effective than fluvastatin monotherapy in patientswith combined hyperlipidemia￡-and is generally safe and well tolerated.